Your shopping cart is currently empty

Olendalizumab (ALXN-1007) is a humanized monoclonal antibody specifically targeting the complement component C5a. The compound binds to C5a, blocking its interaction with the C5aR (CD88) receptor, thereby inhibiting C5a-mediated inflammatory responses, neutrophil chemotaxis, and activation. In clinical and experimental research, Olendalizumab is investigated for treating complement-mediated disorders, such as sepsis, graft-versus-host disease (GVHD), and severe pneumonia or cytokine storms induced by viral infections (e.g., COVID-19).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Olendalizumab (ALXN-1007) is a humanized monoclonal antibody specifically targeting the complement component C5a. The compound binds to C5a, blocking its interaction with the C5aR (CD88) receptor, thereby inhibiting C5a-mediated inflammatory responses, neutrophil chemotaxis, and activation. In clinical and experimental research, Olendalizumab is investigated for treating complement-mediated disorders, such as sepsis, graft-versus-host disease (GVHD), and severe pneumonia or cytokine storms induced by viral infections (e.g., COVID-19). |
| In vitro | In a Gyrolab assay, Olendalizumab demonstrated high specificity as a biotinylated capture reagent (working concentration: 100 µg/mL in Bioaffy wash 1), working alongside AlexaFluor-labeled anti-C5a clone 2942 (4 µg/mL in Rexxip F) to enable precise quantitation of free C5a in human plasma [1]. |
| In vivo | In viral infection models, Olendalizumab acted as a potent C5a inhibitor to mitigate lung injury mediated by complement components (C3, C5a, C5b-9) and receptors (C3aR, C5aR), specifically blocking the non-silent complement activation triggered by coronaviruses [2]. |
| Synonyms | Lendalizumab, ALXN1007 |
| Reactivity | Virus |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | ComplementproteinC5a |
| Cas No. | 2210314-30-8 |
| Isotype | IgG2SA |
| Storage | store at low temperature | -20°C for 2 years, 4°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.